Over the past several decades, monoaminergic system dysfunction has been considered a key factor in the pathophysiology of some mental disorders. However, the therapeutic efficacy of drug therapy based on the monoamine hypothesis is unsatisfactory. In 2008, FDA approved the application of the repetitive transcranial magnetic stimulation (rTMS) for the treatment of patients with depression. Since then, TMS as a non-invasive neuromodulation technique, has been widely used to treat patients with…
